摘要
目的:研究伊伐布雷定治疗射血分数降低的心力衰竭(HFrEF)患者的疗效及其对心脏结构、功能的影响。方法:于我院治疗的104例HFrEF患者被随机均分为常规治疗组和伊伐布雷定组(在常规治疗组基础上加用伊伐布雷定),两组均治疗24周。观察比较两组治疗前后LVEF、心率、血浆N基末端脑钠肽前体(NT-proBNP)水平、6min步行距离(6MWD)、室间隔厚度(IVST)、左室心肌质量指数(LVMI)、左室后壁厚度(LVPWT)、左室舒张内径(LVEDd)及治疗总有效率和不良事件发生率的差异。结果:与治疗前比较,治疗后,两组LVEF、6MWD值均显著升高,心率、血浆NT-proBNP水平、IVST、LVMI、LVPWT、LVEDd值均显著降低,P<0.05或<0.01。与常规治疗组比较,治疗后,伊伐布雷定组IVST[(13.04±0.17)mm比(11.99±0.19)mm]、LVMI[(2.55±0.22)mg/g比(2.41±0.14)mg/g]、LVPWT[(11.79±0.57)mm比(10.14±0.56)mm]降低更显著,P均=0.001。伊伐布雷定组治疗总有效率显著高于常规治疗组(88.46%比65.38%,P=0.005),再入院率显著低于常规治疗组(11.59%比32.69%,P=0.009)。结论:伊伐布雷定能显著改善HFrEF患者心功能,缓解心室重构,疗效显著,安全性好。
Objective:To study therapeutic effect of ivabradine on patients with heart failure with reduced ejection fraction(HFrEF)and its influence on cardiac structure and function.Methods:A total of 104 HFrEF patients treated in our hospital were randomly and equally divided into routine treatment group and ivabradine group(received ivabradine based on routine treatment group),both groups were treated for 24 weeks.LVEF,heart rate(HR),plasma N-terminal pro-brain natriuretic peptide(NT-proBNP)level,6-min walking distance(6MWD),interventricular septal thickness(IVST),left ventricular mass index(LVMI),left ventricular posterior wall thickness(LVPWT),left ventricular end-diastolic dimension(LVEDd)before and after treatment,total effective rate and incidence of adverse events were observed and compared between two groups.Results:Compared with before treatment,after treatment,there were significant rise in LVEF and 6MWD,and significant reductions in HR,plasma NT-proBNP level,IVST,LVMI,LVPWT and LVEDd in two groups,P<0.05 or<0.01.Compared with routine treatment group after treatment,there were significant reductions in IVST[(13.04±0.17)mm vs.(11.99±0.19)mm],LVMI[(2.55±0.22)mg/g vs.(2.41±0.14)mg/g]and LVPWT[(11.79±0.57)mm vs.(10.14±0.56)mm]in ivabradine group,P=0.001 all.Total effective rate of ivabradine group was significantly higher than that of routine treatment group(88.46%vs.65.38%,P=0.005),and rehospitalization rate of ivabradine group was significantly lower than that of routine treatment group(11.59%vs.32.69%,P=0.009).Conclusion:Ivabradine can significantly improve cardiac function and relieve ventricular remodeling in HFrEF patients.The therapeutic effect is significant with good safety.
作者
卢运专
封远锋
赵会必
王仕健
LU Yun-zhuan;FENG Yuan-feng;ZHAO Hui-bi;WANG Shi-jian(Department of Cardiology,People's Hospital of Dongfang City,Dongfang,Hainan,572600,China)
出处
《心血管康复医学杂志》
CAS
2021年第3期287-291,共5页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心力衰竭
心室重构
伊伐布雷定
Heart failure
Ventricular remodeling
Ivabradine
